CELZ: Expands ADAPT Trial
Creative Medical Technology receives FDA clearance to expand its ADAPT clinical trial evaluating CELZ-201 for chronic lower back pain associated with degenerative disc disease
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
CELZ Expands ADAPT Trial
Creative Medical Technology Holdings expands ADAPT trial under new FDA clearance and advances toward Phase 3 planning for Olastrocel in chronic lower back pain